0001415889-24-000758.txt : 20240105 0001415889-24-000758.hdr.sgml : 20240105 20240105141548 ACCESSION NUMBER: 0001415889-24-000758 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240104 FILED AS OF DATE: 20240105 DATE AS OF CHANGE: 20240105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LILLY ENDOWMENT INC CENTRAL INDEX KEY: 0000316011 ORGANIZATION NAME: STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-06351 FILM NUMBER: 24515626 BUSINESS ADDRESS: STREET 1: 2801 NORTH MERIDIAN STREET CITY: INDIANANAPOLIS STATE: IN ZIP: 46208 BUSINESS PHONE: 3179245471 MAIL ADDRESS: STREET 1: 2801 NORTH MERIDIAN ST CITY: INDIANAPOLIS STATE: IN ZIP: 46208 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ELI LILLY & Co CENTRAL INDEX KEY: 0000059478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 350470950 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: LILLY CORPORATE CTR STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 BUSINESS PHONE: 3172762000 MAIL ADDRESS: STREET 1: LILLY CORPORATE CENTER STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 FORMER COMPANY: FORMER CONFORMED NAME: LILLY ELI & CO DATE OF NAME CHANGE: 19941024 4 1 form4-01052024_070143.xml X0508 4 2024-01-04 0000059478 ELI LILLY & Co LLY 0000316011 LILLY ENDOWMENT INC 2801 NORTH MERIDIAN STREET INDIANAPOLIS IN 46208-0068 false false true false 0 Common Stock 2024-01-04 4 S 0 13688 630.238 D 99755122 D Common Stock 2024-01-04 4 S 0 700 631.068 D 99754422 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.00 to $630.99, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.035 to $631.145, inclusive. /s/ Peter A. Buck, Vice President for Investments and Grants Administration, on behalf of Lilly Endowment Inc. 2024-01-05